Metabolic reprogramming signature predicts prognosis and immune landscape in small cell lung cancer: MOCS2 validation and implications for personalized therapy
Our study established a robust metabolism-based prognostic model for SCLC that effectively stratifies patients into risk groups with distinct survival outcomes, immune profiles, and drug sensitivity patterns. Functional validation experiments confirmed MOCS2 as an important regulator of SCLC cell proliferation and migration, providing valuable insights for treatment selection and prognosis prediction in SCLC.
Authors
- Shenghu Guo
- Junyan Wang (ORCID: https://orcid.org/0009-0007-1047-3783)
- Yu Xu (ORCID: https://orcid.org/0000-0003-3386-1379)
- Fan Zhang (ORCID: https://orcid.org/0000-0002-4569-1891)
- Panpan Sun (ORCID: https://orcid.org/0000-0002-0681-6145)
Institutions
- Hebei Medical University (CN)
- Hospital of Hebei Province (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Hebei Mental Health Center (CN)
Publication Details
- Journal
- Frontiers in Molecular Biosciences
- Published
- 2025-05-16
- DOI
- https://doi.org/10.3389/fmolb.2025.1592888
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00